Skip to content
Screener

Amgen AMGN Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)

Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$2.35M
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$578.5M-8.3%

Other financials

Income statement

See full
Revenue$10.1B+9.5%
Gross profit$7.2B+17.4%
Operating income$3.5B+32.3%
Net income$2.4B+65.9%
EPS (diluted)$4.37+64.9%

Balance sheet

See full
Cash & equivalents$574.0M+5.9%
Total debt$57.3B+2.0%
Total equity$11.7B+57.4%
Total assets$95.6B+8.8%

Cash flow

See full
Operating cash flow$4.0B+75.5%
CapEx$513.0M+39.0%
Free cash flow$3.5B+82.6%

Valuation

See full
Market cap$222.32B+43.3%
Enterprise value$279.05B+32.4%
P/E25.4×+2.0×
P/S5.8×+1.4×

Profitability

See full
Gross margin69.5%+5.0pp
Operating margin30%+6.5pp
Net margin23%+4.0pp
FCF margin26.7%-3.7pp

Returns & leverage

See full
Return on equity91.5%-7.7pp
Debt / equity4.9×-2.7×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.

The source filing: Amgen’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000318154-26-000126

During the three months ended June 30, 2026 and 2025, we recognized amortization of our finite-lived intangible assets of $890 million and $1.1 billion, respectively. During the six months ended June 30, 2026 and 2025, we recognized amortization of our finite-lived intangible assets of $1.8 billion and $2.3 billion, respectively. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. As of June 30, 2026, the total estimated future amortization of our finite-lived intangible assets for the remaining six months ending December 31, 2026, and the years ending December 31, 2027, 2028, 2029, 2030 and 2031, was $1.8 billion, $3.6 billion, $2.8 billion, $2.3 billion, $2.2 billion and $2.1 billion, respectively.

Item 1. FINANCIAL STATEMENTS

FAQ

What is Amgen's finite-lived intangible assets - expected amortization expense (year one)?
Amgen (AMGN) reported finite-lived intangible assets - expected amortization expense (year one) of $2.2B in Q2 2026.
How has Amgen's finite-lived intangible assets - expected amortization expense (year one) changed year-over-year?
Amgen's finite-lived intangible assets - expected amortization expense (year one) decreased by 4.3% year-over-year, from $2.3B to $2.2B.
What does finite-lived intangible assets - expected amortization expense (year one) mean?
This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.

Ask your AI about Amgen's finite-lived intangible assets - expected amortization expense (year one).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude